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Background. Antistaphylococcal penicillins including oxacillin and nafcillin are among the drugs of choice for severe and invasive MSSA infections. While alternative agents such as cefazolin are associated with improved safety compared with antistaphylococcal penicillins, comparative safety data between individual antistaphylococcal penicillins is limited and has shown possible improved safety with oxacillin among adults. The objective of this study was to determine the relative adverse events (AEs) reporting for these agents among the FDA Adverse Event Reporting System (FAERS) database.
Methods. We reviewed adverse events reports from the FAERS database from Q4/2003-Q1/2018 and performed a disproportionality analysis of safety events for nafcillin and oxacillin including ADEs related to acute kidney injury (AKI), rash, hypokalemia, and hepatotoxicity. Measures of association evaluated included reporting odds ratio (ROR) and proportion reporting ratio (PRR).
Results. Reports of AKI were substantially more common with nafcillin (PRR 23.2, 3) than oxacillin (PRR 10.9, 95% CI 7.6--15.5). Rash was slightly higher with nafcillin than oxacillin (PRR 3.7, 95% CI 2.8--5.1 vs. 2.6, 95% CI 1.8--3.8). Hypokalemia was substantially more common with nafcillin than oxacillin (PRR 11.8, 95% CI 7.1--19.4 vs. 1.6, 95% CI 0.4--6.4). Hepatotoxcitiy was slightly higher reported among nafcillin than oxacillin (PRR 25.3, 95% CI 14.5--44.3 vs. 12.9, 95% CI 5.8--28.6). Similar observations were seen with RORs ( Figure 1 ).
Figure 1. Reporting Odds Ratios of AEs with Nafcillin and Oxacillin
Conclusion. Oxacillin may be associated with overall improved safety compared with nafcillin based on reporting signals from FAERS. Our results support previous limited observational data. With the likely equal efficacy of these agents, clinicians may want to consider prescribing oxacillin over nafcillin if an antistaphylococcal penicillin is indicated for an invasive MSSA infection. However, given the limitations of reporting systems, further evaluation is warranted.
Disclosures. October 5, 2018: 12:30 PM Background. ASN100 is a combination of two co-administered fully human monoclonal antibodies (mAbs), ASN-1 and ASN-2, that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis. ASN100 is in development for prevention of S. aureus pneumonia in mechanically ventilated patients. A population PK model was developed to characterize the time-course of ASN-1 and ASN-2 in ELF following intravenous administration of ASN100 in healthy subjects.
Methods. A total of 42 healthy subjects received a single dose of ASN-1 or ASN-2 alone (200-4,000 mg) or ASN100 (3,600 or 8,000 mg; 1:1 ratio of ASN-1:ASN-2). All subjects contributed 13-17 serum samples for ASN-1/ASN-2 assay. Twelve subjects contributed 2 bronchoalveolar lavage (BALF) samples each for ELF concentration assay (Day 1 or 2 and Day 8 or 30 after dosing). A previously reported, linear, two-compartment population PK model for serum [ID Week 2017 was expanded and fit to the ELF concentration-time data. Sequential analysis was used to fix serum PK as the driver for ELF PK; only those parameters controlling transfer into and out of the ELF were fit.
Results. An effect-site model adequately described the time-course of ELF concentrations. To allow for estimation of interindividual variability in the elimination from ELF, residual variability in ELF was fixed to that previously estimated for the serum PK data. Separate rate constants for transfer from serum to ELF were estimated for the 3,600 and 8,000 mg ASN100 dose groups to reflect the less than dose-proportional increase in ELF concentrations for both ASN-1 and ASN-2. Goodness-of-fit plots did not reveal any appreciable biases. A visual predictive check indicated that the model could adequately capture the observed data (Figure 1 ). Predicted ELF
